Background and objective: The Medical Research Council dyspnoea score (MRCDS) is a simple, objective scale to assess dyspnoea, the main complaint in patients with chronic interstitial lung disease (ILD). We sought to investigate whether MRCDS is a predictor of outcome in patients with chronic ILD. 
INTRODUCTION
Interstitial lung diseases (ILDs) are a diverse group of mostly chronic lung conditions that include idiopathic interstitial pneumonias or are associated with known aetiologies, including organic and inorganic exposures, autoimmunity and drugs-induced toxicity.
1,2 Some ILDs have a documented response to immunosuppressive treatment, including corticosteroids and cytotoxic agents. 3 Dyspnoea is the cardinal symptom of patients with ILDs and significantly affects their health-related quality of life (HRQOL). Measures of health status and symptom perception are important methods for assessing the impact of chronic ILD and treatment efficacy. 2, 4 Patients significantly benefit from being enrolled in pulmonary rehabilitation programmes, with improvement of exercise capacity and HRQOL. In this context, dyspnoea scores are useful in assessing patient's baseline and monitoring response to rehabilitation. 5 In idiopathic pulmonary fibrosis (IPF), one of the most frequent ILDs, assessing dyspnoea with the Medical Research Council dyspnoea score (MRCDS) provides a simple and useful method of categorizing patients with respect to their activity limitation. 6 The prognostic significance of dyspnoea assessment has been repeatedly elucidated in patients with ILD. 2, 4, 7 MRCDS is an objective scale to measure dyspnoea, based on simple but precise questions. 8 In IPF, MRCDS can be used to monitor disease progression and is an independent predictor of survival. [9] [10] [11] A longitudinal increase of MRCDS from 0-3 to 4-5 was specifically associated with increased mortality in IPF. 10 As one of the most common ILD, most data on dyspnoea scores were published on patients with IPF, while chronic ILDs other than IPF received little attention. Nevertheless, the majority of patients with chronic interstitial involvement are diagnosed with ILD other than IPF. 12 We hypothesized that the MRCDS, as a simple and unexpensive clinical tool, may be a significant predictor of outcome in patients with different types of chronic ILD and may be used to monitor disease progression.
METHODS
Patients diagnosed with chronic ILD between July 2012 and September 2014 at our centre were included in the study. The presence of chronic ILD was defined based on chest HRCT scan and compatible pulmonary function tests (PFTs). After excluding all known causes of ILD, IPF was diagnosed based on a surgical lung biopsy showing a pattern of definite usual interstitial pneumonitis (UIP) and a radiographical pattern of definite or possible UIP in 15 patients and based on a radiographical pattern of definite UIP in 35 patients. 13 The diagnosis of chronic ILD other than IPF was based on clinical presentation, laboratoristic, bronchoscopical, radiographical investigations and when indicated (e.g. non-specific interstitial pneumonia patients) surgical lung biopsies. Subjects with primary cardiac diseases were excluded. The study was approved by the Research Ethics Board of Western University (protocol no. 103186).
The severity of chronic dyspnoea, defined as 'the unpleasant sensation of laboured or difficult breathing', 14 was rated according to MRCDS (Table S1A, Supplementary Information) . 8 Specifically, the MRCDS grades the effect of breathlessness on daily activities essentially measuring perceived respiratory disability. The MRCDS was administered by a physician (M.M.) as part of the routine assessment in our clinic. Three to six-month changes from baseline MRCDS were considered. The MRCDS is part of routine clinical assessment at each visit in our centre. Patients with missing follow-up MRCDS data were excluded. Baseline characteristics, including MRCDS, PFTs and 6-min walk test (6MWT) were obtained at time of diagnosis. PFTs and 6MWT were performed according to the American Thoracic Society (ATS) guidelines. 15, 16 The composite physiologic index (CPI) was calculated according to Wells et al. 17 After diagnosis, patients received follow-up at 3-6 months, at the discretion of the clinician, with systematic reassessment of MRCDS, PFTs and 6MWT.
The primary endpoint was clinical progression within 18 months from the time of diagnosis and baseline MRCDS assessment, defined as either: >10% absolute reduction in forced vital capacity (FVC) percent predicted; >50-m decline in 6-min walk distance (6MWD); admission to hospital for respiratory causes; lung transplantation (LTx) assessment or death (Table S1B , Supplementary Information). The secondary endpoint was 18-month survival from the time of diagnosis, accounting for LTx as a competing event.
Statistical analysis
Details are provided in Appendix S1 (Supplementary Information). Continuous variables were summarized as mean AE SD. Time to endpoints was evaluated using Kaplan-Meier curves and log-rank tests. Cox proportional hazards regression analysis was used to identify significant variables predicting the endpoints. To account for the competing risks of death and LTx, Fine-Gray competing risk regression was used. Receiver operating characteristic (ROC) analysis was used to determine the accuracy of MRCDS in predicting the endpoints (c-statistics). P-values <0.05 were regarded as significant.
RESULTS

Baseline assessment
One hundred and fifteen patients were included in the study: 50 were diagnosed with IPF and 65 with non-IPF chronic ILD (Table 1) . Details are provided in Table 1 . After diagnosis, 75% of subjects with non-IPF chronic ILD were started on immunosuppressive treatment, either corticosteroids and/or one or more cytotoxic therapies (Table 1 ). In the IPF cohort, 19 subjects were started on pirfenidone and 18 on acetylcysteine.
All patients in the IPF cohort and all but four patients (94%) in the non-IPF ILD cohort complained about some degree of exertional dyspnoea at the time of diagnosis. Eight patients in each cohort (16% and 12%, respectively) in the non-IPF ILD cohort had severe dyspnoea at baseline . Average MRCDS at baseline was similar in the two cohorts (2.6 AE 0.9 in the IPF cohort and 2.3 AE 1.1 in the non-IPF ILD cohort). Functional impairment was significant in both cohorts: in the IPF cohort, diffusing lung capacity for carbon monoxide (DL CO ) was 37 AE 12%; in the non-IPF ILD cohort, DL CO was 43 AE 17% (Table 1) .
Outcomes
At the end of the observation period (18 months), 54 (47%) patients experienced clinical progression based on one or more criteria outlined in Table S1B (Supplementary Information); there were 22 deaths related to respiratory causes and 3 LTx. Details are provided in Appendix S2 (Supplementary Information). Baseline characteristics of progressors and nonprogressors were compared (Table S2 , Supplementary Information). While in the IPF cohort MRCDS at baseline was significantly higher in progressors compared with non-progressors, in the non-IPF ILD cohort there Three-month ΔMRCDS: 3-months changes of MRCDS from baseline. Immunosuppressors used included: azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide and anti-TNF-α biological agents.
† Five patients were unable to perform DL CO at baseline due to respiratory limitation. ‡ Six patients were unable to perform DL CO at baseline due to respiratory limitation. § Five patients were unable to perform 6MWD at baseline due to mobility issues and/or respiratory limitation. ¶ Six patients were unable to perform 6MWD at baseline due to mobility issues and/or respiratory limitation. 6MWD, 6-min walk distance; CPI, composite physiologic index; DL CO , diffusing lung capacity for carbon monoxide; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; MRCDS, Medical Research Council dyspnoea score; NSIP, non-specific interstitial pneumonia; UIP, usual interstitial pneumonia.
Respirology (2017) 22, 501-507 © 2016 Asian Pacific Society of Respirology was no significant difference. In both cohorts, however, a longitudinal increase of MRCDS was significantly more frequent in progressors (43% in the IPF and 85% in non-IPF) than in the non-progressors (9% in IPF and 23% in non-IPF).
Outcome predictors
Demographical characteristics at baseline (age, gender and BMI) were not predictive of clinical progression in either cohort. In the IPF cohort, both MRCDS at baseline (hazard ratio (HR) = 1.68, P = 0.0197) and its longitudinal increase (HR = 3.1, P = 0.0047) were significant predictors of progression, while in the non-IPF cohort only the latter was significant, although very strongly (HR = 11.94, P < 0.0001) ( Table 2) . In regard to 18-month mortality, LTx was accounted as a competing event. Baseline MRCDS (HR = 2.88, P = 0.021) was a significant predictor in the IPF cohort, while MRCDS increase did not reach statistical significance (Table S3A , Supplementary Information). In the non-IPF cohort, a longitudinal increase of MRCDS was also a predictor of mortality (HR = 10.75, P = 0.027) ( Table S3B , Supplementary Information). Considering the whole population, clinical progression based solely on either FVC or 6MWD decline or hospital admission was a significant predictor of mortality (HR = 3.25, P = 0.007), still accounting for LTx as competing event.
Accuracy of outcome prediction
In the IPF cohort, MRCDS baseline was associated with clinical progression with intermediate sensitivity (68%) and specificity (59%) (area under the curve (AUC) = 0.68, P = 0.0128), but its longitudinal increase predicted progression with high specificity (91%) and similar, suboptimal sensitivity (62%) (AUC = 0.76, P < 0.0001) ( Table 3, IPF; Fig. 1A ). Considering 18-month mortality as outcome, MRCDS at baseline was confirmed to predict it significantly, with higher sensitivity (87%) than specificity (57%) ( Table S4A , Supplementary Information).
In the non-IPF ILD cohort, MRCDS increase, but not MRCDS baseline values, was associated with clinical progression with both high sensitivity (85%) and specificity (77%) (AUC = 0.81, P < 0.0001) ( Table 3 , non-IPF ILD; Fig. 1C ). Results were very similar when mortality was considered as outcome (Table S4B , Supplementary Information).
Kaplan-Meier curves confirmed that patients with longitudinal increase of MRCDS after diagnosis experienced a significantly higher rate of clinical progression in both cohorts (P < 0.0001; Fig. 1B-D) . Within 18 months from the time of diagnosis, 87% and 68% of the subjects (in the IPF and non-IPF cohort, respectively) with a longitudinal increase of MRCDS experienced clinical progression.
Considering the whole population, baseline MRCDS predicted 18-month mortality (accounting for the competing risk of LTx) significantly and independently together with FVC decline (Model 1, Table 4 ). MRCDS increase also added prognostic value to the CPI (Model 2, Table 4 ).
DISCUSSION
Due to the progressive nature of many ILDs, dyspnoea is both the most frequent and debilitating symptom for patients, profoundly impacting HRQOL. 18 To the best of our knowledge, this is the first study to assess the prognostic value of a simple and relatively objective assessment of dyspnoea with the MRCDS across a large spectrum of chronic ILD. We demonstrated that baseline and longitudinal changes in MRCDS are significant predictors of outcome in chronic ILD, including both IPF and non-IPF ILD. While a higher MRCDS at baseline reflects more advanced disease in patients with IPF and predicts mortality, its reduction or stabilization in patients with non-IPF ILD may reflect response to immunosuppressive therapy. Importantly, an increase of MRCDS from baseline was an independent predictor of mortality, adding prognostic information to FVC decline, which is a well-established parameter of disease progression and to a previously described multidimensional prediction score, the CPI. 17 These findings expand previous data limited to IPF on the role of MRCDS in predicting survival, 10, 11 showing its clinical relevance across a wider range of chronic ILD. Despite the relevant prevalence of ILD other than IPF in the population, 12 this diverse group of conditions received much less attention than IPF. Although the causes of ILDs other than IPF are various, they mostly respond to immunosuppressive treatment, unlike IPF. 2, 3 Although the outcome is generally better than in IPF, ILDs other than IPF still represent one of the most common indications for LTx 19 and are increasingly referred to pulmonary rehabilitation. 20, 21 Different scales have been developed to assess dyspnoea in patients with chronic lung disease. Examples include the Borg score, 22 Baseline Dyspnoea Index and University of California San Diego Shortness of Breath Questionnaire, 23 Dyspnoea-12 Questionnaire 4 and the MRCDS. 7, 8 In both chronic ILD and COPD, dyspnoea scales showed significant correlations with the physical and mental components of HRQOL. 7, 24 The MRCDS is the only scale that has been so far associated with outcome in chronic lung disease, including IPF 25 and COPD, for which the MRCDS is integral part of the multi-dimensional BODE index. 26 We demonstrated that an increase of MRCDS independently predicted poor outcome in both IPF and non-IPF cohorts, adding prognostic information to the common use of FVC decline. Yorke et al. demonstrated only weak correlations between MRCDS and measures of lung function and 6MWD in chronic ILD, suggesting that the MRCDS is able to capture different aspects of the complex pathophysiology of these conditions, 4 including concomitant emphysema and pulmonary hypertension. 27 Kozu et al. stratified IPF patients with the MRCDS according to their peripheral muscle force and were able to predict the potential benefit from rehabilitation individually. 6 MRCDS was also significantly associated with parameters of ventilatory constraint on cardiopulmonary exercise testing, reflecting physiological derangements that limit exercise capacity 28 and with objective parameters of physical activity. 29 The present study expands the previous findings on the role of dyspnoea scores in the assessment of chronic respiratory disease. We analysed the prognostic value of MRCDS with a variety of statistical approaches, taking also into account the competing risk of LTx and death. ROC analysis (c-statistics) showed an association between MRCDS longitudinal increase from baseline and progression of disease with high sensitivity (85%) and specificity (77%, AUC = 0.81) in the non-IPF cohort and with high specificity (91%) and intermediate sensitivity (62%; AUC = 0.76) in the IPF cohort. This finding may partially be related to a 'ceiling effect', with IPF patients diagnosed with advanced disease at baseline Clinical progression is a multi-dimensional endpoint based on objective criteria used in clinical trials of ILD. 30, 31 Importantly, clinical progression (when based only on FVC or 6MWD decline or hospital admission for respiratory causes) significantly predicts mortality in the population of this study. Baseline MRCDS was not a significant predictor of clinical progression in non-IPF ILDs. This observation probably reflects the capacity of patients with even advanced ILDs other than IPF at the time of diagnosis to respond to shortterm immunosuppressive treatment, which is not seen in IPF. A total of 18 out of 65 patients in the non-IPF cohort experienced an improvement of their symptoms at the first longitudinal reassessment.
The population included in this study had on average a clinically significant involvement from their chronic ILD, with substantial reduction of lung function, exercise capacity and a 40% (non-IPF chronic ILD) to 56% (IPF) rate of progression, despite medical therapy. The availability of reliable predictors of outcome is essential to help clinicians make important decisions in the management of chronic lung disease, such as switching therapy, referral to LTx and monitoring of the response to pulmonary rehabilitation. 21 Being inexpensive, easily repeatable and reflecting both disease severity and treatment response, the MRCDS may in future become part of the systematic assessment of chronic ILD together with PFTs and established prediction models, as supported by the multivariate analysis results.
Patients with IPF are significantly impaired in terms of HRQOL and dyspnoea is the most important determinant of health status. 18 Further studies are needed to determine the optimal instrument to measure HRQOL and symptom experience of patients diagnosed with chronic ILD. Multi-dimensional scores could potentially improve the assessment of these patients across different domains. 12 In our study, while the CPI was associated with outcome in patients with IPF, it did not reach statistical significance in patients with non-IPF ILD. The latter result should be interpreted with caution, as CPI was designed in patients with IPF only. 17 This study has several limitations. First, the study included patients with a variety of ILDs, who may have different responses to medical management, although the population was homogeneous in terms of functional and exercise impairment. The consistency of the data across chronic ILD in this study may increase the generalizability of the results. Second, dyspnoea as a symptom remains subjective in nature and the MRCDS may be less responsive to small changes. Third, the retrospective nature of the study and the lack of validation cohort implies that results should be confirmed in larger, prospective studies. However, baseline was always considered from the time of diagnosis and the endpoint criteria were objective in nature. Lastly, only one component of breathlessness was measured (perceived respiratory disability).
In conclusion, the longitudinal assessment of dyspnoea with a simple scale such as the MRCDS in patients with chronic ILD reflects disease severity and allows to predict the progression of disease and mortality with reliable accuracy. Adding prognostic value to the use of lung function decline, this inexpensive tool, if validated in prospective studies, may be useful in clinical practice together with other functional and radiographical parameters to monitor the clinical course of disease in order to predict outcome. 
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